APACMed: Riding The Tailwind Of Health Care And Medtech Through The Pandemic And Beyond
COVID-19 has not put the brakes on the resurgence of health care, say Asia-based VC investors
VC investors and medtech strategists alike at APACMed’s 2020 virtual conference agreed that the challenges presented by COVID-19 have given healthtech a higher profile and accelerated the arrival of health system workflow improvements.
You may also be interested in...
COVID-19 business volatility continues to impact the medtech industry, but Royal Philips is targeting modest comparable sales growth for 2020 after posting quarterly growth of 10%.
Germany’s COVID-19 testing strategy now permits the use and reimbursement of coronavirus antigen tests.
Diagnosing and mapping COVID-19 are the keys to controlling the pandemic, and the IVDs industry is crucial to their success. But unclear messaging from the center is not helping, says incoming BIVDA chief operating officer Helen Dent.